• Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients 

      Debik, Julia Barbara; Euceda, Leslie R.; Lundgren, Steinar; Gythfeldt, Hedda; Garred, Øystein; Borgen, Elin; Engebråten, Olav; Bathen, Tone Frost; Giskeødegård, Guro F. (Journal article; Peer reviewed, 2019)
      Patients with locally advanced breast cancer have a worse prognosis compared to patients with localized tumors and require neoadjuvant treatment before surgery. The aim of this study was to characterize the systemic metabolic ...
    • Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial 

      Røssevold, Andreas Hagen; Andresen, Nikolai Kragøe; Bjerre, Christina Annette; Gilje, Bjørnar; Jakobsen, Erik Hugger; Raj, Sunil Xavier; Falk, Ragnhild Sørum; Russnes, Hege Elisabeth Giercksky; Jahr, Thea; Ruud, Randi Margit; Lømo, Jon; Garred, Øystein; Chauhan, Sudhir Kumar; Lereim, Ragnhild Reehorst; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Peer reviewed; Journal article, 2022)
      Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated ...
    • Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer 

      Gythfeldt, Hedda von der Lippe; Lien, Tonje Gulbrandsen; Tekpli, Xavier; Silwal-Pandit, Laxmi; Borgen, Elin; Garred, Øystein; Skjerven, Helle; Schlichting, Ellen; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian; Engebråten, Olav (Peer reviewed; Journal article, 2020)
      Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for ...
    • Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1) 

      Ohnstad, Hege Oma; Blix, Egil Støre; Akslen, Lars Andreas; Gilje, Bjørnar; Raj, Sunil Xavier; Skjerven, Helle; Borgen, Elin; Janssen, Emiel; Mortensen, Elin Synnøve; Brekke, Marianne B.; Falk, Ragnhild Sørum; Schlichting, Ellen; Boge, Beate; Songe-Møller, Silje; Olsson, Pernilla Marie A.; Heie, Anette; Mannsåker, Bård; Vestlid, Magdalena Aas; Kursetgjerde, Torgunn; Gravdehaug, Berit; Suhrke, Pål; Sánchez, E.; Bublevic, J.; Røe, Oluf Dimitri; Geitvik, Gry; Halset, Eline Holli; Rypdal, Maria Christine; Langerød, Anita; Lømo, Jon; Garred, Øystein; Porojnicu, Alina Carmen; Engebraaten, O.; Geisler, Jürgen; Lyngra, Marianne; Hansen, M. H.; Søiland, Håvard; Nakken, T.; Asphaug, Lars; Kristensen, Vessela N.; Sørlie, Therese; Sørlie, T.; Nygård, Jan Franz; Kiserud, Cecilie E.; Reinertsen, Kristin Valborg; Russnes, Hege Elisabeth Giercksky; Naume, Bjørn (Journal article; Peer reviewed, 2024)